O'Connor Alternative Investments’s Atrium Therapeutics RNA Stock Holding History
Bought
Maintained
Sold
Other funds holding RNA
O'Connor Alternative Investments's RNA Position: Q3 2026 in Review
O'Connor Alternative Investments reduced its Atrium Therapeutics (RNA) stake by 6.3% in Q3 2026, selling an estimated $447K and leaving 559,142 shares worth $4.63M. The position accounts for 0.23% of the portfolio, ranked #56.
O'Connor Alternative Investments first reported a position in RNA in Q1 2026 and has held it in 3 quarters since. The position peaked at $8.03M in Q2 2026. 148 funds tracked by Wall St. Rank hold RNA as of Q3 2026.
- O'Connor Alternative Investments held 559,142 shares of Atrium Therapeutics worth $4.63M as of Q3 2026.
- O'Connor Alternative Investments sold 37,876 Atrium Therapeutics shares in Q3 2026, an estimated $447K.
- Atrium Therapeutics made up 0.23% of O'Connor Alternative Investments's portfolio in Q3 2026, its #56 holding.
- O'Connor Alternative Investments first reported a position in Atrium Therapeutics in Q1 2026 and has held it in 3 quarters since.
- O'Connor Alternative Investments's Atrium Therapeutics position peaked at $8.03M in Q2 2026.
- 148 funds tracked by Wall St. Rank held Atrium Therapeutics as of Q3 2026.
Based on O'Connor Alternative Investments's 13F filing for Q3 2026, filed 16 Nov 2026.